NEW YORK & DURHAM, N.C.– Medidata, a Dassault Systèmes company, today announced that Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, is using Medidata to standardize its clinical trial platform for building out its decentralized clinical trial (DCT) technology offerings. This will enable Rho to provide rapid reporting of cross-domain, cross-study data in decentralized trials, where data collection methods have become more numerous, varied, and complex.
“Forward-thinking CROs, such as Rho, are rapidly making the necessary platform and accreditation investments to enable sponsors to move into a hybrid and/or fully decentralized approach to managing clinical trials,” said Joan Shaiman, senior vice president, partners at Medidata. “Rho has been a valued partner with Medidata for over ten years and provides its clients with deep clinical trial management expertise in neurology, respiratory, rare diseases and orphan drugs.”
Rho made the strategic decision to invest in Medidata’s single platform to provide flexible and agile support for future business growth. This clinical technology capability and expertise will advance efforts to accelerate sponsors’ clinical development programs by giving them complete access to their clinical and operational data and enhancing its utilization to inform decision-making.
“By partnering with Medidata – a trusted leader in this space – we are further committing to sponsors that we can meet and exceed their future needs, especially as the market evolves from traditional clinical trials toward a more decentralized and patient-focused approach,” said Dr. Laura Helms Reece, CEO, Rho. “This investment will give us an important competitive advantage as we strive to be ahead of the curve, as the industry continues to evolve in response to advancing technologies and the need for greater diversity and inclusion in clinical trials. A key element will be streamlined, real-time visibility into patient data and quality metrics throughout a decentralized trial, from inception to study conclusion.”
Medidata’s end-to-end platform helps its clients attract and win more sponsor bids, while reducing study build time, saving money on unexpected data migrations and transfers, and speeding up data reconciliation and cleanup.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
